Dr. Lavoie is a General Partner with TVM Capital Life Science, an international venture capital firm with more than $1 billion under management. Dr. Lavoie is responsible for deal making, deal origination and execution and for the management of portfolio companies in the US and Canada. Dr. Lavoie has led investments into Montreal-based TVM companies Kaneq Bioscience and FAAH Pharma, where she serves on the Boards of Directors. Dr. Lavoie also serves on the board of Acer Therapeutics, located in Cambridge, MA. Prior to TVM, Dr. Lavoie was with VG Partners, a large Canadian private equity firm, where her most recent role was as Partner and head of life sciences. She served on the boards of therapeutics and device companies including Cytochroma (sold to Opko Health) and Trillium Therapeutics (TSX: TR). Dr. Lavoie also had a direct role in the sale of VisualSonics, an imaging company, to SonoSite Inc. (now Fujifilm SonoSite). Previously, Dr. Lavoie was a marketing strategy consultant with drug/device developer Vasogen (merged with Intellipharmaceutics; NASDAQ: IPCI).